Fintel · Sep 17, 2026
HA
NYSE · HAE
Haemonetics Corporation
Healthcare · Medical - Instruments & Supplies
$105.30
Down-$0.70 (-0.66%)
Updated Sep 26, 2026, 5:04 PM
SID Score
6.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.12B
- P/E ratio
- 23.87
- Dividend yield
- 0.00%
- 52-week range
- $47.32 – $110.45
- Volume
- 492.6K
- Avg. volume
- 976.76K
Price performance
HAE price history
1M range · 20 trading sessions · Daily adjusted prices
HAE closed at $105.30 after 20 trading sessions, up 1.29% for the selected period.
- Last close
- $105.30
- Period change
- +1.29%
- Period low
- $101.06
- Period high
- $108.73
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $105.72 | $106.58 | $104.71 | $105.30 | 492.6K |
| Sep 24, 2026 | $106.67 | $108.22 | $105.92 | $106.00 | 416.8K |
| Sep 23, 2026 | $108.56 | $110.28 | $106.70 | $106.82 | 704.88K |
| Sep 22, 2026 | $109.26 | $110.14 | $108.38 | $108.52 | 446.6K |
| Sep 21, 2026 | $109.24 | $110.055 | $108.05 | $108.73 | 327.03K |
| Sep 18, 2026 | $108.95 | $110.45 | $107.60 | $108.40 | 1.3M |
| Sep 17, 2026 | $108.39 | $109.83 | $107.56 | $107.60 | 621.12K |
| Sep 16, 2026 | $105.90 | $106.78 | $104.78 | $106.24 | 520.72K |
| Sep 15, 2026 | $105.14 | $106.87 | $103.24 | $106.20 | 440.03K |
| Sep 14, 2026 | $106.98 | $107.47 | $102.835 | $106.31 | 887.94K |
| Sep 11, 2026 | $101.70 | $102.89 | $100.53 | $102.69 | 458.31K |
| Sep 10, 2026 | $102.02 | $102.95 | $100.595 | $101.06 | 602.32K |
| Sep 9, 2026 | $102.15 | $103.18 | $100.57 | $103.16 | 612.22K |
| Sep 8, 2026 | $101.89 | $103.525 | $101.25 | $102.84 | 581.59K |
| Sep 4, 2026 | $101.59 | $103.565 | $101.51 | $102.92 | 425.09K |
| Sep 3, 2026 | $103.69 | $104.05 | $101.73 | $102.85 | 602.06K |
| Sep 2, 2026 | $102.24 | $104.37 | $101.61 | $102.92 | 777.67K |
| Sep 1, 2026 | $103.60 | $104.16 | $101.08 | $101.95 | 633.65K |
| Aug 31, 2026 | $103.06 | $103.95 | $101.39 | $103.07 | 494.69K |
| Aug 28, 2026 | $104.59 | $105.61 | $103.57 | $103.96 | 659.23K |
Latest HAE news
The latest Smart Investors Daily articles mentioning HAE.
Stock researchCompany · Overview
HAE research
Overview
Company profile and research snapshot.
Company profile
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $82.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 17, 2026 | Citigroup | Buy | — |
| Sep 3, 2026 | Raymond James | Outperform | — |
| Aug 21, 2026 | Baird | Outperform | — |
| Aug 19, 2026 | Barrington Research | Outperform | — |
| Aug 18, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 17, 2026
Roblox downgraded, Hershey upgraded: Wall Street's top analyst calls
Roblox downgraded, Hershey upgraded: Wall Street's top analyst calls
Benzinga · Sep 17, 2026
This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.
Benzinga · Sep 17, 2026
Citigroup Upgrades Haemonetics to Buy, Raises Price Target to $123
Citigroup analyst Joanne Wuensch upgrades Haemonetics (NYSE:HAE) from Neutral to Buy and raises the price target from $92 to $123.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
